Liquidia Corp LQDA
Institutional shares held
44.3 Million
1.55M
calls
1.52M
puts
Total value of holdings
$538M
$18.9M
calls
$18.4M
puts
Market Cap
$810M
64,362,300
Shares Out.
Institutional ownership
68.83%
# of Institutions
171
We take great care to ensure that the data presented and summarized in this overview for Liquidia Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LQDA
View all-
Patient Square Capital LP Menlo Park, CA7.18MShares$90.4 Million26.66% of portfolio
-
Black Rock Inc. New York, NY4.24MShares$53.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$43.3 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.29MShares$41.4 Million0.17% of portfolio
-
Findell Capital Management LLC New York, NY3.19MShares$40.2 Million16.08% of portfolio
-
Kynam Capital Management, LP Princeton, NJ2.27MShares$28.5 Million1.86% of portfolio
-
State Street Corp Boston, MA2.18MShares$27.4 Million0.0% of portfolio
-
Whitefort Capital Management, LP New York, NY1.7MShares$21.4 Million9.05% of portfolio
-
Opaleye Management Inc. Boston, MA1.7MShares$21.4 Million3.1% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$18.9 Million1.14% of portfolio
Latest Institutional Activity in LQDA
Top Purchases
Top Sells
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Insider Transactions at LQDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 14
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
16,393
-2.78%
|
$180,323
$11.78 P/Share
|
|
Jan 14
2025
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
22,343
-2.15%
|
$245,773
$11.78 P/Share
|
|
Jan 14
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,809
-2.6%
|
$52,899
$11.78 P/Share
|
|
Jan 14
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
23,370
-5.5%
|
$257,070
$11.78 P/Share
|
|
Jan 14
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,362
-3.74%
|
$91,982
$11.78 P/Share
|
|
Jan 14
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,249
-2.26%
|
$68,739
$11.78 P/Share
|
|
Jan 11
2025
|
Russell Schundler General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
102,543
+14.81%
|
-
|
|
Jan 11
2025
|
Roger Jeffs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
229,327
+18.05%
|
-
|
|
Jan 11
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+2.07%
|
-
|
|
Jan 11
2025
|
Jason Adair Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,895
+25.47%
|
-
|
|
Jan 11
2025
|
Michael Kaseta CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
112,797
+20.97%
|
-
|
|
Jan 11
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,729
+23.75%
|
-
|
|
Jan 11
2025
|
Rajeev Saggar Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,780
+20.6%
|
-
|
|
Dec 02
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
1,091
-0.35%
|
$12,001
$11.51 P/Share
|
|
Dec 02
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.35%
|
$6,006
$11.51 P/Share
|
|
Dec 02
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
455
-0.38%
|
$5,005
$11.51 P/Share
|
|
Dec 02
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
1,063
-0.22%
|
$11,693
$11.51 P/Share
|
|
Nov 30
2024
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,343
+0.74%
|
-
|
|
Nov 30
2024
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+1.2%
|
-
|
|
Nov 30
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,563
+1.29%
|
-
|
Last 12 Months Summary
Buy / Acquisition
2.49M
Shares
From
22
Insiders
| Grant, award, or other acquisition | 1.93M shares |
|---|---|
| Open market or private purchase | 487K shares |
| Exercise of conversion of derivative security | 64K shares |
| Open market or private sale | 459 shares |
Sell / Disposition
3.81M
Shares
From
8
Insiders
| Open market or private sale | 372K shares |
|---|---|
| Other acquisition or disposition | 3.44M shares |